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Cell fusion promotes chemoresistance in metastatic colon
carcinoma
V Carloni1, A Mazzocca2, T Mello3, A Galli3 and S Capaccioli4
Chemoresistance is an important concern in the treatment of metastatic colon cancer. It may emerge through selection of clones
that are inherently resistant from the outset or through mechanisms acquired during treatment. Cell fusion represents an efficient
means of rapid phenotypic evolution that make cells with new properties at a rate exceeding that achievable by random
mutagenesis. Here, we first identified a number of proteins involved in cell fusion using a shotgun proteomics approach, then we
investigated the role of these proteins namely tetraspanin CD81/CD9, ADAM10, GTP-binding protein a13, radixin, myosin regulatory
light chain and RhoA in the regulation of colon cancer cell fusion. We also found a previously unrecognized role of ADAM10, Ga13
and RhoA in promoting cell fusion. Finally, we show that the occurrence of cell fusion in a metastatic model of colon carcinoma
causes the appearance of cells resistant to both 5-fluorouracil and oxaliplatin. These findings highlight the importance of cell fusion
in cancer progression and raise significant implications for overcoming chemoresistance in metastatic colon cancer.
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INTRODUCTION
Survival times of patients with advanced colon cancer have
increased over the last decade, primarily as a result of treatment
with combinations of cytotoxic agents. However, the clinical
benefits of these therapies are short-lived and restricted to
subgroups of patients. Resistance to cytotoxic drugs is the main
cause of therapeutic failure, which usually recurs with a multidrug
resistance (MDR) phenotype shortly after dramatic response to
initial treatments. Some molecular mechanisms of drug resistance
are known. Two well-characterized drug efflux pumps,
P-glycoprotein and MDR-related protein, have been thought to
be crucial for MDR. However, the importance of these mechanisms
remains still controversial. For example, ectopic expression of
these pumps induces partial resistance in comparison with that
achieved by long-term drug selection.1,2 Clinical studies have also
revealed that expression of these pumps was rarely observed and
did not necessarily correlate with the outcome in colon cancer.3
Therefore, these proteins cannot completely account for the
appearance of a MDR phenotype of colon cancer and other
mechanisms must be involved in this process. 5-Fluorouracil
(5-FU), leucovorin and oxaliplatin (Oxa) represent a therapeutic
regime (FOLFOX) commonly used in the treatment of patients
with advanced colon cancer.4–6 Resistance to therapy occurs in
nearly all patients with metastatic colon cancer, and patients that
acquire resistance have a disease progression with few
therapeutic options. As the gain of drug resistance involves the
acquisition of a new phenotype, we hypothesized that the
generation of fused cells in metastatic colon cancer could
represent a phenomenon responsible of MDR. In recent years,
accumulating experimental evidence has suggested a possible
broad involvement of cell fusion during the initiation, progression
and phenotypic diversification of cancer.7–9 Cell fusion is a process
in which two cells become one by merging their plasma
membranes.10–12 The role of cell fusion in metastasis has been
recently demonstrated. This represents an efficient means of rapid
phenotypic evolution during tumor progression that make cells
with new properties at a rate exceeding that achievable by
random mutagenesis.13
In spite of the diversity of cell types that undergo fusion, the
underlying cellular processes, including cell–cell adhesion, align-
ment and membrane mixing, are similar irrespective of the cell
type.14 In this regard, tetraspanins and ADAMs (A Disintegrin And
Metalloprotease domain) proteins have been implicated in cell
fusion processes. In particular, tetraspanin CD9 and CD81 have
been implicated in muscle cell fusion, mononuclear phagocytes
and linked to the virus-induced syncitium formation.15–17 ADAMs
were initially discovered as proteins involved in fertilization,
muscle fusion and organ development.18,19 In this study, we
provide evidence that proteins ADAM10, GTP-binding protein a13,
radixin, myosin regulatory light chain and RhoA promote cell
fusion in colon cancer cells. In addition, we demonstrate that cell
fusion results in the acquisition of a resistant phenotype to both
5-FU and Oxa, two pharmacological agents commonly employed
in the treatment of advanced colon cancer.
RESULTS
Identification of distinct proteins associated with CD81 by shotgun
proteomics
Because of the implication of tetraspanin CD81 in cell fusion and
in an attempt to identify and characterize the proteins associated
with CD81, we immunoprecipitated CD81 from Triton X-100 cell
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lysates of human colon cancer cells, SW480. To eliminate
background proteins not effectively associated with CD81, we
used an IgG1 antibody as control. Any protein identified in both
conditions was not considered as a protein associated with CD81.
The immunoprecipitated proteins were digested with trypsin and
peptides were subsequently identified by shotgun proteomics.20
The proteomic analysis led to the identification of 51 proteins
(Supplementary Information Table S1). We found different classes
of molecules associated to CD81, including tetraspanin CD9,
molecules mediating adhesion with extracellular matrix (that is,
integrins), cell–cell adhesion (that is, EpCAM, CD44), signaling
proteins (that is, heterotrimeric G protein subunits) and the
disintegrin-like metalloproteinase ADAM10. Of the proteins
identified in this screen, CD81, CD9 have been implicated in cell
fusion, whereas less is known about the role of ADAM10. First, we
verified the cellular colocalization of CD81 and CD9 with ADAM10
in SW480 by immunofluorescence and found that CD81 and CD9
colocalize with ADAM10 in punctuate structures (Figure 1a). Then,
we addressed the cellular colocalization of CD9 with ADAM10 in
the CD81-negative murine colon cancer cells, CT26. Similarly,
these cells showed a robust colocalization of CD9 with ADAM10 in
punctuate structures (Figure 1b).
The next step was to assess the physical interaction of CD81 and
CD9 with ADAM10 by immunoprecipitation experiments. These
revealed that CD81 and CD9 are indeed associated with ADAM10,
a protein migrating at 78 kD under nonreducing conditions
(Figure 1c). Most ADAMs, including ADAM10, possess the
typical HEXGHXXGXXH motif at their catalytic site, which is
responsible for the zinc-dependent protease activity. We therefore
assessed the presence of proteolytitc activity associated with
CD81 and CD9 by using gelatin zymography. The detection of a
collagenolytic band migrating atB78 kD confirmed the presence
of ADAM10 in the CD81/CD9-immunoprecipitated complexes
(Figure 1d).
Figure 1. Association of CD81 and CD9 with ADAM10 in colon carcinoma cells. (a) Representative images showing colocalization of ADAM10
(red) with CD81 and CD9 (green) in SW480 human colon carcinoma cells. (b) Representative images showing colocalization of ADAM10 (red)
with CD9 (green) in CT26 murine colon carcinoma cells, scale bars 20 mm. (c) Co-immunoprecipitation (IP) of ADAM10 with CD81 in both cell
lysates and culture medium supernatants (SN) of SW480 cells (left panel). Co-immunoprecipitation of ADAM10 with CD9 in both cell lysates
and culture medium SN of CT26 cells (right panel). (d) Immunoprecipitation of CD81 or CD9 followed by gelatin zymography revealed that
CD81 and CD9-associated ADAM10 was functionally active in both cell lysates and culture medium SN of SW480 and CT26 cells.
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Colon carcinoma cell fusion is promoted by ADAM10 that is stably
associated to CD81 and/or CD9
We focused our attention on the role of ADAM10 and its structural
domains in regulating cell fusion. Hence, we cloned a bovine
ADAM10 cDNA, whose amino-acidic sequence is identical to the
human ADAM10, into a plasmid expressing a monomeric red
fluorescent protein tagged to ADAM10 (ADAM10-RFP). The
ADAM10-RFP cDNA was then ectopically expressed in CT26. We
observed the appearance of binucleate or multinucleate CT26 cells
when the ADAM10-RFP-transfected CT26 cells were grown in the
presence of geneticin, an antibiotic used to select ADAM10-RFP
stable transfectants (Supplementary Information Figure S1A). We
assumed that this aspect was allegedly due to cell fusion and
eventually enhanced by ADAM10 overexpression. Therefore, we
next evaluated whether the multinucleated phenotype induced
by ADAM10 was restricted only to CT26 cells or whether this was a
more general phenomenon. To this end, human colon cancer cells
HCT116 not expressing CD81 were stably transfected with
ADAM10-RFP and evaluated for the presence of the multi-
nucleated phenotype as performed with ADAM10-RFP-CT26
transfectants. Similar to CT26, HCT116 cells expressing ADAM10-
RFP showed the presence of multinucleated cells (Supplementary
Information Figure S1B). These findings indicate that ectopic
expression of ADAM10 increased the fusogenic competence in
both human and murine colon cancer cell types.
To further substantiate the involvement of ADAM10-RFP in
promoting cell fusion, we co-cultured CT26-EGFP stable transfec-
tants with CT26-ADAM10-RFP stable transfectants for 2 days. Fused
cells were identified by dual color FACScan (BD FACSCalibur,
San Jose, CA, USA). As shown in Figure 2a, right panel, ectopic
expression of ADAM10-RFP accounted for the presence of a large
number of fused cells (28%) in comparison with control (8.9%), left
panel, and the subsequent scatter measurement revealed an
increase in cell size of fused cells (Figure 2b).
To visualize cell fusion, we take advantage of live-cell imaging.
We therefore seeded an equal number of untransfected and
ADAM10-RFP-transfected CT26 cells onto a layer of Matrigel and
performed time-lapse confocal microscopy for 18 h (64 800 s). The
cell mixture was imaged by capturing a single confocal section at
the indicated times. A representative animated sequence of the
imaged cells is shown in supplementary information Movie S1.
As shown in Figure 2c, the cell–cell contact between ADAM10-
RFP-CT26 transfectants and untransfected CT26 resulted, in this
latter, in altered cell shape (upper and middle panels) and in a
disruption of the cell membrane followed by cell fusion (lower
panels). Taken together, these results imply that expression of
ADAM10 promotes cancer cell fusion.
Reduced expression of CD9 increases cell fusion in the CT26 and
HCT116 cells
The role of CD81 and CD9 in cancer cell fusion is at the present
barely defined, therefore, we tested whether inhibition of CD9
expression in the CD81-negative CT26 and HCT116 cells would
affect their fusion ability. To do so, we used a short hairpin-
interfering RNAs (shRNA) targeted against the coding region of
the mouse and human CD9 gene. As shown in Figure 3a,
expression of CD9-shRNA results in a reduction of both mRNA and
CD9 protein expression levels in CT26 cells as evaluated by flow
cytometry and RT–PCR, respectively. A control-shRNA (CTL-shRNA)
did not cause a reduction of CD9 expression (Figure 3a). Similarly,
expression of CD9-shRNA results a reduction of both mRNA
and CD9 protein expression levels in HCT116 cells (Figure 3b).
Notably, the reduced expression of CD9 enhanced the percentage
of fused cells in both CT26 and HCT116 cell lines in comparison
with CT26 and HCT116 transduced with control-shRNA. Collec-
tively, our data suggest that the presence of CD9 may prevent
colon cancer cell fusion.
Cysteine-rich domain of ADAM10 is required for CD81 and CD9
association with ADAM10 and supports colon carcinoma cell
adhesion
The findings that ADAM10 promotes cell fusion of CT26 and
HCT116 prompted us to investigate whether carcinoma cells
attached to the extracellular portion of ADAM10. To study the
involvement of ADAM10 domains in promoting cell adhesion, we
performed experiments using recombinant ADAM10 truncation
mutants and different colon carcinoma cell lines (CT26, SW480
and HCT116). In particular, the recombinant domains of ADAM10
were tagged with EGFP at COOH terminus to allow their detection,
and then expressed in COS-7 cells (Figure 4a). To determine the
interaction of the recombinant mutants of ADAM10 with
tetraspanin CD81, we took advantage by the fact that COS-7 cells
were negative for CD81 expression. Hence, we co-expressed EGFP-
tagged ADAM10 mutants and the human pcDNA 3.1 vector
harboring CD81 in COS-7 cells. The physical association was then
analyzed by co-immunoprecipitation in both cell lysates and
culture medium supernatants. As shown in Figure 4b, CD81 was
detected in immunoprecipitates from cells expressing full-length
ADAM10 (ADAM10-EGFP), disintegrin and cysteine-rich domain
and cysteine-rich domain alone (Cys-EGFP) but not in those
expressing the transmembrane and intracytoplasmic domain
(TMCyt-EGFP). Interestingly, we detected the presence of endo-
genous CD9 in the immunoprecipitates of these variants. This is in
agreement with a previous study showing that microvesicles
containing both CD81 and CD9 are released by cells in the culture
medium.21 These results clearly demonstrate the association of
CD81 and CD9 with ADAM10. Even more important, our data
elucidate a crucial role for the cysteine-rich domain of ADAM10 in
mediating association with CD81 and CD9.
A fundamental feature of cell fusion is the juxtaposition of two
plasma membranes. To evaluate a possible involvement of
ADAM10 in this process, we addressed the ability of CT26 to
interact with ADAM10. As shown in Figure 4c, CT26 cells attached
to: (1) recombinant disintegrin and cysteine-rich domain,
(2) cysteine-rich domain alone and (3) full-length ADAM10. No
cell attachment was observed to the transmembrane/cytoplasmic
domain. A similar adhesion pattern was observed in analog
experiments carried out with SW480 and HCT116 cells.
ADAM10 and CD81 regulate localization of GTP-binding a13
We hypothesize that tetraspanin CD81 and CD9 and ADAM10
contribute to bringing the opposing membranes into close
proximity in fusogenic cancer cells and that, in a subsequent
step, these proteins can recruit intracellular proteins forming
multi-protein complexes at the sites of fusion. To explore this
hypothesis, we went back to our proteomic data and focused on
GTP-binding protein a13. Ga13 acts as a signal transducer for G
protein-coupled receptor as well as for non-G protein-coupled
receptor. As illustrated in Figure 5a, ADAM10 and CD81 showed a
prominent colocalization with Ga13 in SW480 cells. A robust
colocalization of ADAM10 and CD9 was also observed in CT26 cells
(Figure 5b). To learn more about the localization of Ga13,
we cotransfected a RFP vector with CD81-GFP, as shown in
Supplementary Information Figure S2A, and a RFP-tagged Ga13
with CD81-GFP (Supplementary Figure S2B). We observed
colocalization of RFP-Ga13 with CD81-GFP at cellular cortex and
induction of cell rounding in CT26 and HCT116 cultured on a two-
dimensional glass-bottomed dishes (Supplementary Figure S2B).
These data clearly indicate that Ga13 takes part in the plasticity of
the plasma membrane and the remodeling of the cytoskeleton.
However, a fundamental question remained about how CD81
and ADAM10 are organized in paired living cells plunged in a
three-dimensional substrate. To this end, we cotransfected CT26
cells with CD81-GFP and RFP-Ga13, suspended them in gelled
Matrigel and immediately analyzed by fluorescence microscopy.
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Figure 2. Ectopic expression of ADAM10 promotes cell fusion in colon carcinoma. (a) CT26 cells stable transfectants expressing ADAM10-RFP
(red image) and CT26 stable transfectants expressing EGFP empty vector (green image) were co-cultured for 2 days and the fused cells (yellow
image) were then quantified by dual color FACScan. In the left panel, fluorescence dots in panel Q2 represent cells fused expressing both
EGFP and RFP proteins. In the right panel, fluorescence dots in panel Q2 represent cells fused expressing both EGFP and ADAM10-RFP
proteins. (b) Nuclear size was measured following 4,6-diamidino-2-phenylindole (DAPI), staining of fixed cells (left panel) whereas cell size was
measured by flow cytometry as forward scatter (rigth panel). One representative experiment out of two is shown. (c) Tracking of CT26 cell
fusion by live-cell imaging. An equal number of non-labeled CT26 and CT26 expressing ADAM10-RFP (red) were mixed, included into a layer of
Matrigel and immediately analyzed by time-lapse confocal microscopy for 18 h (see also Supplementary Information, Movie S1). The cell
mixture was imaged by capturing a single confocal section at the indicated times (30min each). Cell-to-cell contact of a CT26 expressing
ADAM10-RFP (red) with a non-labeled CT26 is indicated with a white arrow. Cell fusion was observed between a positive ADAM10-RFP-CT26
cell and a non-RFP-labeled CT26 cell. In non-RFP-labeled CT26 cells, the cell-to-cell contact leads to cell shape modifications (upper and
middle panels) and consecutively to disruption of the cell membrane (lower panels). In the last panel, immediately after the fusion, ADAM10-
RFP was localized in the cytosol of the non-labeled CT26 cell, indicating an exchange of the ADAM10-RFP between cells. Scale bars 20 mm.
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As shown in Supplementary Figure S3A, we noticed a significant
colocalization of both proteins CD81 and Ga13 to the juxtaposi-
tion of cell membrane. Next, we evaluated the cellular localization
of ADAM10-RFP and CD81-GFP (Supplementary Figure S3B). We
observed that ADAM10-RFP is localized in both intracellular
vesicles and at cell–cell contact, and that this cellular distribution
was paralleled by CD81-GFP. Similarly, colocalization of ADAM10-
RFP with EGFP-Ga13 was evident around the cell membrane
confirming in living cells the findings observed analyzing the
endogenous proteins (Supplementary Figure S3C).
Interaction of SW480 and CT26 with ADAM10 stimulates RhoA
activity
As the interaction of Ga13 with RhoA leads to an increase in
cell cortical tension as well as in disruption of plasma
membrane–cortical actin,22,23 we investigated whether the
interaction of SW480 and CT26 cells with ADAM10Cys-EGFP or
ADAM10-EGFP activates Rho small GTPase. To this end, we
performed a GTP-RhoA pull-down assay. First, we observed a
colocalization of endogenous CD81 with RhoA to the plasma
membrane in SW480 and CD9 with RhoA in CT26 cells (Figure 6a).
Similarly, endogenous ADAM10 is colocalized with RhoA to the
plasma membrane in SW480 and CT26 cells (data not shown).
Second, SW480 and CT26 cells stimulated with ADAM10Cys-EGFP
or ADAM10-EGFP resulted in increased levels of GTP-RhoA.
Increased levels of GTP-RhoA were also obtained with the ectopic
expression of Ga13 in the same cell lines (Figure 6b). These data
indicate that CD81/CD9/ADAM10 or CD9/ADAM10 complexes
stimulates RhoA activity in interacting cells and disclose an
involvement of Ga13 in this process.
Figure 3. CD9 knockdown in CT26 and HCT116 cells results in augmented fusion ability. (a) Retrovirally transduced CT26 with a negative
control shRNA (CTL-shRNA) and a shRNA targeted against the coding region of the mouse CD9 gene (CD9-shRNA) were selected in
puromycin-containing medium and, after 1–2 weeks, the decreased expression of CD9 protein and mRNA was assessed by flow cytometry and
RT–PCR. The endogenous GAPDH mRNA level was measured as internal control, (left panels). Next, CD9-silenced CT26 were stably transfected
with EGFP and mixed with CT26 stably transfected with RFP in the presence of geneticin. Fused cells were identified by dual color FACScan.
Each bar represents the mean±s.d. *Po0.05 (right panel). (b) Human colon carcinoma HCT116 cells, with endogenous expression levels of
ADAM10 and CD9 but not expressing CD81 (upper panels) were retrovirally transduced with a negative control (CTL-shRNA) and with a shRNA
against human CD9 (CD9-shRNA). Decreased expression levels of CD9 protein and mRNA were assessed by flow cytometry and RT–PCR. The
endogenous GAPDH mRNA level was measured as internal control, (left panels). Next, CD9-silenced HCT116 were stably transfected with EGFP
and mixed with HCT116 stably transfected with RFP in the presence of geneticin. Fused cells were identified by dual color FACScan. Each bar
represents the mean±s.d. *Po0.05 (right panel).
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ADAM10 causes Ga13-dependent myosin light-chain
phosphorylation in colon carcinoma cells
The cell cortex is a network of cross-linked actin filaments whose
tension levels are modified by external or internal cues. The
cortical tension in cancer cells is mainly regulated by phosphor-
ylation of the myosin light chain 2, also referred to as myosin
regulatory light chain. Thus, we evaluated the levels of phospho-
myosin light chain 2 (Ser19) in SW480 and CT26 cells after plating
onto dishes coated with ADAM10Cys-EGFP or ADAM10-EGFP.
We found that SW480 and CT26 plated on ADAM10-EGFP-coated
dishes display increased levels of MLC2 phosphorylation, whereas
cells lacking Ga13 as a consequence of knockdown by siRNA
showed a remarkable reduction of phosphorylation of the myosin
light chain 2 (Ser19) (Figures 6a and d). These data clearly
demonstrate that the interaction of cells with ADAM10 causes
phosphorylation of MLC2 and that the interaction of Ga13 with
RhoA positively influences this final event leading to an increase in
myosin ATPase activity and cell contraction.24
Reduced phosphorylation levels of ERM proteins following
interaction of SW480 and CT26 with ADAM10
Cortical contractility is exceptionally high in tumor cells and the
tension build up can induce disruption of the cell cortex at sites
Figure 4. ADAM10 association with CD81 and CD9 requires cysteine-rich domain. (a) EGFP-tagged ADAM10 truncation mutants were
expressed in COS-7 cells. (b) The association between ADAM10 and CD81 was analyzed by co-immunoprecipitation (IP) in both cell lysates
and culture medium supernatants. CD81 (upper panel) was detected in immunoprecipitates of lysates from full-length ADAM10-, DisCys
ADAM10- and CysADAM10-expressing cells but not in those from TMCyt ADAM10. The lower panel shows the presence of endogenous CD9
in the immunoprecipitates of full-length ADAM10, DisCys ADAM10 and CysADAM10. One representative experiment out of three is shown.
(c) Colon carcinoma cells adhesion to ADAM10. HCT116, SW480 and CT26 were plated onto dishes coated with ADAM10-EGFP,
ADAM10DisCys-EGFP, ADAM10Cys-EGFP or ADAM10TMcyt-EGFP as described in Materials and methods. Each bar represents the mean±s.d.
of triplicate wells of three independent experiments.
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where plasma membrane and cortical actin interactions are locally
reduced. In this regard, the ERM proteins (ezrin, radixin and
moesin) function as linkers between the plasma membrane and
the actin cytoskeleton, thus providing structural strength to the
cell cortex.25 Phosphorylation at a carboxy-terminal threonine
residue (Thr567 of ezrin, Thr564 of radixin, Thr558 of moesin),
which disrupts their amino- and carboxy-terminal association, has
a key role in modulating the conformation and function of ERM
proteins.26 To this end, we evaluated the phosphorylation levels of
ERM proteins using SW480 and CT26 cells plated onto
ADAM10Cys-EGFP- or ADAM10-EGFP-coated dishes or maintain-
ed in suspension. As shown in Figure 6e, cells plated onto plastic
revealed the presence of two phosphorylated proteins. In
particular, the upper band corresponding to radixin/ezrin was
strongly phosphorylated in both SW480 and CT26 cell lines.
Conversely, when the cells were plated onto ADAM10Cys-EGFP
and ADAM10-EGFP or maintained in suspension for 60min
phosphorylation of proteins was undetected. Taken together,
these data suggest that the interactions of CD81/CD9/ADAM10 or
CD9/ADAM10 complexes in opposing fusogenic cancer cells
increase cortical tension and initiate events of cortical actin
membrane destabilization at the cell–cell contact that eventually
induce cell fusion. Thus, to analyze a possible involvement of
Ga13-Rho pathway in the aforementioned mechanism, we used a
dominant-negative variant of Rho (N19RhoA), in which Ser19 is
changed to Asn (N). The ectopic expression of N19RhoA has been
demonstrated to inhibit endogenous Rho function and the
Ga13–RhoA pathway by forming non-productive complexes with
guanine nucleotide exchange factors (GEFs) for Rho.27 The ectopic
expression of N19RhoA significantly reduced the percentage of
fused CT26 cells whereas the expression of control acGFP1 vector
had no effect (Figure 6f).
Appearance of drug resistant to both 5-FU and Oxa as a
consequence of cell fusion in metastatic colon carcinoma
We next sought to investigate the involvement of cell fusion in
selecting chemoresistant cells to 5-FU and Oxa in metastatic colon
Figure 5. GTP-binding a13 protein associates to components of tetraspanin CD81/CD9 multi-protein complex. (a) Representative images
showing endogenous ADAM10, CD81 and Ga13 staining in SW480 cells. Staining shows a prominent colocalization of ADAM10 and CD81
with Ga13. (b) Representative images showing endogenous ADAM10, CD9 and Ga13 staining in CT26 cells. Staining shows a robust
colocalization of ADAM10 and CD9 with Ga13. Inset magnifies the colocalization of proteins to the plasma membrane. Scale bars, 20 mm.
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carcinoma. To this end, we transduced both CT26 cells, resistant to
5-FU, and CT26 cells resistant to Oxa with RFP and GFP retroviral
vectors, respectively, or with ADAM10 cysteine domain-GFP
(AD10CysGFP). Syngeneic mice were injected with a mixed cell
population of RFP- and AD10CysGFP-CT26-positive cells or with a
mixed population of RFP- and GFP-CT26-positive cells as control.
As expected, parental CT26 cells showed an aggressive behavior
as demonstrated by the massive presence of metastatic nodules in
the liver within 2 weeks after intrasplenic inoculation (Figure 7a).
The cells isolated from metastatic nodules were treated with 5-FU,
Oxa or with both drugs and cell survival then analyzed by
dual color FACScan. As shown in Figure 7b, CT26-OxaR fused
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spontaneously with CT26-5FUR in vivo. In addition, the ectopic
expression of cysteine-rich domain ADAM10 increased the
number of fused cells resistant to both 5-FU and Oxa in liver
metastases from colon cancer (Figure 7c). We observed an
average fusion percentage of 9.8% in RFPþ /GFPþ mixed cell
population and 18.4% in RFPþ /AD10CysGFPþ (Figure7d). Taken
together, these data demonstrate the occurrence of cell fusion in
metastatic colon carcinoma as well as the involvement of cell
fusion in the appearance of tumor cell subpopulations resistant to
both 5-FU and Oxa.
DISCUSSION
Colon cancer can usually be cured by surgical excision at any
stage before metastases to distant sites (i.e., liver, lung) are
established. Understanding the basic aspects of this process has
obvious and important implications for clinical research. However,
many questions still remain. For example, how many mutations
are required for a particular metastatic cell population to acquire a
widespread chemoresistance? Recent studies have established
that the great majority of the mutations present in metastases are
also present in the primary colon carcinoma. In addition, the
process of ex vivo cell culture of tumors excised from patients does
not introduce new mutations into colon tumor cell populations.28,29
It is reasonable that an alternative mechanism must be involved in
this process and that, in this context, cell fusion contributes to
widespread chemoresistance by combining genes responsible for
resistance to various drugs. Here, we have shown that cell fusion is
driven by ADAM10 in colon carcinoma and this induces
chemoresistance to both 5-FU and Oxa. Fusion between tumor
cells with distinct phenotypes can generate cells with new
properties at a rate exceeding that achievable by random
mutagenesis, thereby allowing a better adaptation to survive to
the therapeutic treatments. Metastatic subpopulations might thus
be more able to evolve under selective pressures than non-
metastatic cells, by a process other than mutation.30
Recent findings showing that chronic inflammation dramatically
increases the frequency of cell fusion of hematopoietic cells with
various cell lineages31,32 may account for the high fusogenicity of
metastatic tumor cells, as inflammation is often associated with
the tumor microenvironment and metastatic cells may trigger an
inflammatory response once they colonize the liver. Recently, it
has also been described that metastatic tumor cells are able to
induce TNF-a production by Kupffer cells and these latter
constitute the major source of TNF-a in tumor cell-inoculated
livers.33 In agreement with the aforementioned observations, our
results show that metastatic cancer cells fuse spontaneously
in vitro and in vivo. This is in line with another recent report by Lu
and Kang showing that organotropisms of metastatic cells can be
acquired through spontaneous fusion between cancer cells with
bone and lung tropism that eventually generates populations of
cells capable of metastasizing to both organs.13 Finally, our study
discloses a mechanism by which ADAM10 promotes fusion in colon
cancer cells. Along this line, we propose that in a context of
fusogenic cancer cells, ADAM10 may initiate a combination of
events that lead to local disruption of interactions between
plasma membrane and cortical actin and the consequent plasma
membrane fusion. The role of ADAM10 in regulating plasma
membrane–cortical actin at sites of cell–cell contact is particularly
important in three-dimensional environments and in vivo.
In addition, our study highlights that enhanced expression of
ADAM10 in colon cancer cells has biological consequences that can
be attributed to the presence of additional non-catalytic ADAM10
domains (i.e., cysteine-rich domain). This further implies that not all
functions of ADAM10 in colon cancer cells will be abolished by
effective protease inhibitors. Here we have also found that both
Ga13 and Rho activity contribute to cell fusion through an increase
in cell cortical tension as well as in disruption of plasma
membrane–cortical actin interactions. Our study demonstrates not
only the implication of ADAM10 in stimulating Ga13-mediated
activation of RhoA and phosphorylation of myosin regulatory light
chain, but it also shows a Ga13-dependent regulation of ERM
proteins. It has been reported that Ga13 directly interacts with
radixin, a member of ERM proteins, and that this interaction results
in a conformational activation of radixin.34 This phenomenon is
possibly due to competition between components of the Rho
signaling pathway (for example, p115 Rho GEF) and radixin for
Ga13 binding, (see Figure 8). Finally, these findings emphasize the
role that ADAM10 and the cytoskeleton play in promoting
metastatic cancer cell fusion.
In conclusion, this study demonstrates a crucial role for cell
fusion in colon carcinoma that makes cancer cells more resistant
to conventional chemotherapeutic agents. The information
derived from this study may have two relevant immediate
consequences in the development of more efficient pharmacolo-
gical strategies against metastatic colon cancer. First, the
possibility of targeting hidden actions of multi-task metallopro-
teases such as ADAM10, and particularly its contribution to cancer
cell fusion. Second, a better understanding of the biology of fused
cancer cells will contribute to identify and employ specific
inhibitors in the treatment of colon cancer.
MATERIALS AND METHODS
Cell lines and antibodies
SW480 and HCT116 human colon carcinoma cell lines, CT26 murine colon
carcinoma cell line were purchased from ATCC (Rockville, MD, USA). Cos-7
cells were from ATCC.
Expression of ADAM10 truncation mutants
The plasmid pcDNA3-ADAM10 coding for wild-type bovine ADAM10
(GenBank: Z21961.1) was used as template to clone and insert ADAM10
Figure 6. CD81/CD9/ADAM10 complex stimulates RhoA activity, Ga13-dependent myosin light chain phosphorylation and reduces
phosphorylation of ERM proteins. (a) Immunofluorescence staining showing the localization of CD81 with RhoA in SW480 and CD9 with RhoA
in CT26 cells plated on cover slips coated with ADAM10Cys-EGFP. Inset magnifies the colocalization of proteins to the plasma membrane.
Scale bars, 20mm. (b) SW480 and CT26 cells were plated on ADAM10-EGFP, ADAM10Cys-EGFP captured on plastic dishes through a coating of
the wells with antibodies directed against the tagging protein EGFP. Proteins from lysates were immunoblotted with antibodies directed
against RhoA. GTP-bound RhoA was measured by association with GST–Rhotekin rho-binding domain (GST-RBD) beads. RFP-Ga13 notation
means ectopic expression of protein. CTL notation means coating of dishes with antibodies anti-EGFP. (c) Ga13 siRNA-transfected SW480 and
CT26 cells were plated on ADAM10Cys-EGFP (AD10cys) captured on plastic dishes through a coating of the wells with antibodies directed
against the tagging protein EGFP. Proteins from lysates were immunoblotted with antibodies to phospho-myosin light chain 2 (Ser19). CTL-
siRNA notation means scrambled siRNA-transfected cells. (d) Immunoblot of SW480 and CT26 cell lysates showing reduced levels of Ga13
when this protein is knocked down. a-tubulin represents the loading control. (e) SW480 and CT26 cells were plated onto dishes coated with a
supernatant of ADAM10-EGFP- transfected Cos-7 cells, with a supernatant of ADAM10Cys-EGFP transfectants or with a supernatant of Cos-7
cells maintained in suspension. Cells were then lysed and extracted proteins immunoblotted with antibodies to phospho-Ezrin (Thr567)/
Radixin(Thr564)/Moesin(Thr558). (f ) The column bar graph represents the percentage of CT26 fused cells measured in a mixed population of
cells transduced with RFPþ /AcGFP1þ and RFPþ /N19RhoA-AcGFP1þ . Each bar represents the mean±s.d. *Po0.01.
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into pEGFP-N1 (Clontech, Mountain View, CA, USA) or pTagRFP-N1
(Evrogen, Moscow, Russia) plasmids and for the construction of ADAM10
truncation mutants by PCR using XhoI and KpnI restriction enzymes.
Cell adhesion assay
Cell culture 24-well plate were coated with an anti-EGFP antibody by
placing the antibody dilution (30mg/ml) in the well plate.35 The plate was
Figure 7. Cell fusion in selecting chemoresistant cells to 5-FU and Oxa in a syngeneic metastatic model of colon carcinoma.
(a) A representative pattern of liver metastases following intrasplenic inoculation of wild-type CT26 in syngeneic mice is shown (left
panel). Hematoxylin and eosin staining of a representative liver section showing a metastatic colon carcinoma lesion (right panel) NL, normal
liver; T, tumor. (b) Syngeneic mice were injected with CT26 cells resistant to 5-FU labeled with RFP (left panel), CT26 cells resistant to Oxa
labeled with GFP (middle panel) or with a mixed cell population of RFP and GFP CT26-positive cells (right panel). The cells isolated from the
metastatic nodules were treated with 5-FU, Oxa or with both drugs and cell survival analyzed by dual color FACScan. RFPþ, GFPþ and RFPþ /
GFPþ events were gated and shown as contour plot. (c) Syngeneic mice were injected with CT26 cells resistant to 5-FU labeled with RFP, CT26
cells resistant to Oxa labeled with ADAM10 cysteine-rich domain-GFP (AD10CysGFP) or with a mixed cell population of RFP and AD10CysGFP
CT26-positive cells. The cells isolated from metastatic nodules were treated with 5-FU, Oxa or with both drugs and cell survival analyzed by
dual color FACScan. RFPþ, AD10CysGFPþ and RFPþ / AD10CysGFPþ events were gated and shown as contour plot. (d) The column bar graph
represents the percentage of fused cells measured as double-positive cells divided by total number of cells selected within the setting limits
of flow cytometer.
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gently rocked overnight at 4 1C before the solution was aspirated.
The protein binding sites of each well was blocked with sterile
phosphate-buffered saline (PBS) containing 3% (w/v) BSA for 60min at
37 1C. The blocking solution was aspirated and replaced with PBS as
control or supernatant of Cos-7 transfected with ADAM10-EGFP,
ADAM10DisCys-EGFP, ADAM10Cys-EGFP or ADAM10TMCyt-EGFP. The
coating with supernatant was performed at 37 1C for 60min. After a
rinse with PBS, 500ml of the cell suspension (5 104/ml) was added to the
wells for 60min at 37 1C. The plate was rinsed twice in serum-free
Dulbecco’s modified Eagle medium and the cells fixed for 5min in
methanol, rinsed in PBS and stained with 0.1% crystal violet in 10%
methanol (vol/vol). Absorbance was measured with an ELISA reader
(Bio-Rad, Hercules, CA, USA) at 590 nm. A blank value corresponding to an
empty well was automatically subtracted.
Flow cytometry and time-lapse confocal microscopy
For flow cytometry analysis, CT26 or HCT116 stable transfectants
expressing EGFP or ADAM10-RFP were obtained by selection with
geneticin. CT26-EGFP stable transfectants (106 cells) were mixed with
CT26-ADAM10-RFP stable transfectants (106 cells) in the presence of
geneticin. Fused cells were identified by dual color FACScan. For time-lapse
microscopy experiments, we suspended an equal number of untransfected
CT26 cells with ADAM10-RFP-transfected CT26 cells onto a layer of Matrigel
plated on 60-mm glass-bottomed cell culture plates. Live imaging was
performed at 37 1C using a Leica TCS SP2 confocal microscope with an
aerated incubation chamber for long-term experiments with living cells.
For immunofluorescence microscopy, cells were washed with PBS, fixed
with 2.5% paraformaldehyde for 10min, and then blocked 1 h with 3%
goat normal serum in 0.05% Triton X-100. Cells were sequentially
incubated with primary and Cy3- or Cy2-conjugated secondary antibodies.
Retroviral infections
We cloned by PCR the EcoRI- and SalI-flanked insert from plasmid pRetroQ
ADAM10-GFP containing ADAM10 Cys-rich domain-GFP cDNA into retro-
viral vector pBabe-puro (Addgene, Cambridge, MA, USA). Furthermore, we
cloned the EcoRI and XhoI-flanked fragment from vector pRetroQ-
DsRedmonomer (Clontech), containing the full-length monomeric RFP cDNA,
into retroviral vector pLXSN (Clontech).
Cell fusion in a syngeneic model of murine colon cancer
metastasis
The cell lines CT26-OxaR and CT26-5FUR resistant, respectively, to
chemotherapeutic drugs Oxa and 5-FU were obtained by selection in
increasing concentrations of Oxa 10–25mM and 5-FU 7.5–15mM. CT26-OxaR
and CT26-5FUR were infected with virus-containing supernatant and
observed at least for two passages in vitro to verify that fluorescence
intensity was stably expressed. CT26-OxaR expressing RFP, CT26-5FUR
expressing GFP, CT26-5FUR expressing ADAM10 CysGFP or an equal
mixture of these cells were injected into mice. Six-week-old male BALB/c
mice were purchased from Charles River Laboratories (Lecco, Italy) and
liver metastases were generated by intrasplenic injection of 1 105 cells in
PBS (50ml). After 2 weeks, the livers were removed and the extracted
metastases plated on dishes were cultured under sterile conditions.
Outgrown cells were treated for a week with both 25mM of Oxa and 15mM
of 5-FU to select for resistant cells and the survival cells were analyzed by
dual color flow cytometry.
Statistical analysis
All data are expressed as means±s.d. Statistical analysis was performed by
Student0s t-test (analysis with GraphPad Prism).
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